Medifast (MED) Tops Q2 EPS by 16c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Medifast (MED) PT Raised to $249 at DA Davidson
August 3, 2018 8:52 AM EDTDA Davidson raised its price target on Medifast (NYSE: MED) to $249.00 (from $201.00) while maintaining a Buy rating.
Analyst Linda Bolton Weiser commented, "MED exceeded consensus for 2Q18 sales and EPS--sales were +55% to $117M, exceeding consensus of $102M by 15%, and accelerating from 40% growth in 1Q18. EPS... More
